A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia

Journal: Nature Medicine

Published: 2020-03-30

DOI: 10.1038/s41591-020-0806-7

Affiliations: 18

Authors: 20

Go to article
Institutions Share
Duke University Health System, United States of America (USA) 0.32
NIH National Institute of Mental Health (NIMH), United States of America (USA) 0.10
Case Western Reserve University (CWRU), United States of America (USA) 0.10
Yale University, United States of America (USA) 0.10
McLean Hospital, United States of America (USA) 0.08
Baylor College of Medicine (BCM), United States of America (USA) 0.08
NYU Langone Medical Center (NYULMC), United States of America (USA) 0.05
Indiana University (IU), United States of America (USA) 0.03
Michael E. DeBakey VA Medical Center (MEDVAMC), United States of America (USA) 0.03
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA) 0.03
Nash Family Department of Neuroscience, ISMMS, United States of America (USA) 0.03
The University of Sydney (USYD), Australia 0.03
UCSF Medical Center, United States of America (USA) 0.02
Indiana University - Purdue University Indianapolis (IUPUI), United States of America (USA) 0.02
Durham VA Medical Center (VAMC), United States of America (USA) 0.02

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER